Bulgaria Pharmaceuticals market among less attractive and corruption remains a problem, says BMI
Bulgaria as one of the less attractive pharmaceutical markets in the Emerging Europe region, says market research group Business Monitor International. For the Q410 update to BMI’s Business Environment Ratings (BERs), Bulgaria is ranked 15th of the 20 markets surveyed in the region, while globally it ranks 53rd out of the total of 77 markets assessed in our ever-expanding pharmaceutical universe.
While the country's regulatory environment is largely considered adequate, especially given the increased controls over prescribing and dispensing practices, the value of the pharmaceutical market will be limited by poor market dynamics, health care debts and prolonged economic difficulties.
Market forecast to reach $1.42 billion by 2014
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze